Trade Emergent BioSolutions Inc. - EBS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8.04 |
| Open | 7.85 |
| 1-Year Change | 225.73% |
| Day's Range | 7.85 - 8.3 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 8.02 | 0.33 | 4.29% | 7.69 | 8.31 | 7.68 |
| Dec 19, 2024 | 8.04 | -0.19 | -2.31% | 8.23 | 8.30 | 7.98 |
| Dec 18, 2024 | 8.13 | -0.65 | -7.40% | 8.78 | 8.78 | 7.99 |
| Dec 17, 2024 | 8.72 | 0.08 | 0.93% | 8.64 | 8.81 | 8.31 |
| Dec 16, 2024 | 8.83 | 0.35 | 4.13% | 8.48 | 8.99 | 8.34 |
| Dec 13, 2024 | 8.40 | -0.33 | -3.78% | 8.73 | 8.79 | 8.31 |
| Dec 12, 2024 | 8.66 | 0.18 | 2.12% | 8.48 | 8.85 | 8.38 |
| Dec 11, 2024 | 8.54 | -0.09 | -1.04% | 8.63 | 8.63 | 8.30 |
| Dec 10, 2024 | 8.54 | -0.06 | -0.70% | 8.60 | 8.66 | 8.48 |
| Dec 9, 2024 | 8.72 | -0.26 | -2.90% | 8.98 | 8.98 | 8.59 |
| Dec 6, 2024 | 8.91 | -0.33 | -3.57% | 9.24 | 9.50 | 8.82 |
| Dec 5, 2024 | 9.13 | 0.00 | 0.00% | 9.13 | 9.31 | 9.02 |
| Dec 4, 2024 | 9.40 | 0.13 | 1.40% | 9.27 | 9.46 | 9.10 |
| Dec 3, 2024 | 9.26 | -0.42 | -4.34% | 9.68 | 9.79 | 9.07 |
| Dec 2, 2024 | 9.80 | -0.17 | -1.71% | 9.97 | 10.05 | 9.53 |
| Nov 29, 2024 | 10.08 | 0.00 | 0.00% | 10.08 | 10.40 | 9.97 |
| Nov 27, 2024 | 10.06 | 0.08 | 0.80% | 9.98 | 10.26 | 9.80 |
| Nov 26, 2024 | 10.00 | 0.31 | 3.20% | 9.69 | 10.04 | 9.50 |
| Nov 25, 2024 | 9.84 | 0.43 | 4.57% | 9.41 | 10.09 | 9.41 |
| Nov 22, 2024 | 9.43 | 0.13 | 1.40% | 9.30 | 9.62 | 9.26 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Emergent BioSolutions Company profile
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, it offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, the company offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. Emergent BioSolutions Inc. has a development and manufacturing agreement with Novavax Inc. for coronavirus disease vaccine candidate. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.| Industry: | Pharmaceuticals (NEC) |
400 Professional Dr, Suite 400
GAITHERSBURG
MARYLAND 20879
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com